🟢 NEW WEBINAR VIDEO AVAILABLE: Research Insights: Latest Updates on Ongoing Studies
Webinar: Research Insights: Latest Updates on Ongoing Studies A summary of the latest webinar and Q&A session On October 23rd, the European Huntington Association held an engaging and informative webinar titled “Research Insights: Latest Updates on Ongoing Studies.” The session was expertly moderated by Professor Ă…sa PetersĂ©n, an HD clinician and researcher, and included participation […]
We better get moving! The significance of physical activity for HD patients and the role of physiotherapy
We better get moving! The significance of physical activity for HD patients and the role of physiotherapy While the scientific community keeps working to develop pharmacological treatments, it is important that we focus on improving quality of life and adopting habits that are beneficial for our health. Physical activity is one of those habits that […]
PTC announced promising 12 month results from their Phase 2 PIVOT-HD study of oral PTC518
Breaking News PTC today announced promising 12 month results from their Phase 2 PIVOT-HD study of oral PTC518 PTC today announced promising 12 month results from their Phase 2 PIVOT-HD study of oral PTC518.  At Month 12, mutant Huntingtin (mHTT) in the blood was lowered by 22% and 43% respectively for 5mg and 10mg doses. A similar result was seen in cerebrospinal fluid, where mHTT was […]
uniQure Receives FDA Regenerative Medicine Advanced Therapy (RMAT)Designation for Investigational Gene Therapy AMT-130 in Huntington’s Disease
Breaking News uniQure Receives FDA RMAT Designation for Investigational Gene Therapy AMT-130 in HD Uniqure‘s gene therapy for Huntington’s Disease, named AMT-130 has passed a significant next step. Today the company announced that the US regulators, FDA, has granted them a Regenerative Medicine Advanced Therapy (RMAT) designation. The designation is given based on 3 criteria: […]
THE EUROPEAN ELECTIONS SHAPE OUR FUTURE – YOUR VOTE IS IMPORTANT!
THE EUROPEAN ELECTIONS SHAPE OUR FUTURE – YOUR VOTE IS IMPORTANT! The European Elections Will Be Held From The 6th To The 9th Of June Across The Eu. This week will be an important one for the future of the EU. The 705 Members of the European Parliament, who will be in charge of decision […]
THE EU PARLIAMENT ELECTIONS ARE AROUND THE CORNER… WHY SHOULD WE VOTE?
THE EU PARLIAMENT ELECTIONS ARE AROUND THE CORNER… WHY SHOULD WE VOTE? The 705 Members of the European Parliament (MEPs) that are elected, shape the future of 450 million European citizens – including ours. The European Parliament elections take place every five years, and they are held to elect the Members of the European Parliament […]
Eurordis Conference 2024
The EHA at the 12 th European Conference on Rare Diseases and Orphan Products The Rare Disease Community is Better Together! Last week, the European Huntington Association attended the European Conference on Rare Diseases and Orphan Products organized by EURORDIS in Brussels. This is the biggest conference focusing on rare diseases. These were two intense […]
Huntington Dance
Taking advantage of the fact that… we’ve got the moves. #HuntingtonDance Did you know that Huntington’s Disease wasn’t always known by this name? It has changed throughout history, but all its names have always had something in common: they have been related to dance! This year we wanted to take advantage of this fact, and […]
Prilenia webinar 2024
A deeper dive into Prilenia’s updates about Pridopidine application for market authorization A summary of the latest webinar and Q&A session with Prilenia On March 18th, we had a webinar with Henk Schuring, Chief Regulatory and Commercialization Officer at Prilenia, and Anne Rosser, Professor at Cardiff University, where we had the opportunity to better understand […]
Prilenia news 2024
Breaking News Prilenia will ask for market approval at the EMA Today, Prilenia made a groundbreaking announcement, revealing that they are going to apply for market authorization at the European Medicines Agency (EMA) within the next few months. This marks a historic moment as the first-ever medicine for Huntington’s Disease (HD) reaches this critical stage. […]